EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo

Oncology Letters

Volumn 4, Issue 1, 2012, Pages 135-140

  Xia, Hui ^a   Yu, Chang Hai ^a   Zhang, Yiming ^a   Yu, Jianqi ^a   Li, Jie ^a   Zhang, Wen ^a   Zhang, Baoshi ^a   Li, Yingjie ^a   Guo, Nannan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cooperative; EZHE2; Ionizing radiation; Lung cancer; Small interfering RNA

Indexed keywords

SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GAMMA IRRADIATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; IRRADIATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; RADIOSENSITIVITY; RNA INTERFERENCE; SURVIVAL RATE; TUMOR XENOGRAFT;

EID: 84861328765     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.696     Document Type: Article

References (13)

1. Fidias P and Novello S: Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 28: 5116-5123, 2010.
2. Fuld AD, Dragnev KH and Rigas JR: Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother 11: 1387-1402, 2010.
3. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, et al: Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446: 815-819, 2007.
4. Francis H and Solomon B: The current status of targeted therapy for non-small cell lung cancer. Intern Med J 40: 611-618, 2010.
5. Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, et al: EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 69: 9211-9218, 2009.
6. Lennes IT and Lynch TJ: Quality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer. Clin Lung Cancer 10: 341-346, 2009.
7. Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, Ikeda H, Nimura Y, Nagino M and Nakanuma Y: Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci 101: 355-362, 2010.
8. Fujii S, Ito K, Ito Y and Ochiai A: Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283: 17324-17332, 2008.
9. Tsang DP and Cheng AS: Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 26: 19-27, 2011.
10. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD and Kleer CG: Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 28: 843-853, 2009.
11. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, et al: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114: 2733-2743, 2009.
12. Panousis D, Patsouris E, Lagoudianakis E, Pappas A, Kyriakidou V, Voulgaris Z, Xepapadakis G, Manouras A, Athanassiadou AM and Athanassiadou P: The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors. Eur J Gynaecol Oncol 32: 156-159, 2011.
13. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N and Rotter V: Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23: 5759-5769, 2004.